4/A: Sutro Biopharma CFO Edward Albini Corrects Stock Unit Grant in Amended SEC Filing
SEC Filing (Form 4/A)
Edward Albini, CFO of Sutro Biopharma, files an amended SEC Form 4 to correct the number of restricted stock units (RSUs) granted on March 5, 2024.
Summary
- Edward Albini, CFO and Secretary of Sutro Biopharma, filed an amended Form 4 with the SEC on March 22, 2024.
- The amendment corrects the number of restricted stock units (RSUs) granted to Albini on March 5, 2024.
- The corrected filing shows that Albini was granted 69,000 RSUs on March 5, 2024.
- These RSUs vest in equal annual installments beginning on March 1, 2025, contingent upon continued service.
- Each RSU represents the right to receive one share of Sutro Biopharma's common stock upon settlement.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.
Stakeholder Impact
- The correction of the RSU grant ensures accurate reporting to shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of the original transaction (grant of RSUs). |
| 03/07/2024 | Date of original Form 4 filing. |
| 03/01/2025 | First vesting date for the RSUs (1/4th of the total award). |
| 03/01/2028 | Expiration date of the RSUs. |
| 03/22/2024 | Date of the amended Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.